uniQure N.V. (QURE)
NASDAQ: QURE · Real-Time Price · USD
23.43
-0.97 (-3.98%)
At close: Feb 20, 2026, 4:00 PM EST
23.08
-0.35 (-1.51%)
After-hours: Feb 20, 2026, 7:48 PM EST
uniQure Revenue
uniQure had revenue of $3.70M in the quarter ending September 30, 2025, with 61.83% growth. This brings the company's revenue in the last twelve months to $15.75M, down -44.90% year-over-year. In the year 2024, uniQure had annual revenue of $27.12M with 71.17% growth.
Revenue (ttm)
$15.75M
Revenue Growth
-44.90%
P/S Ratio
92.66
Revenue / Employee
$75,364
Employees
209
Market Cap
1.46B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 27.12M | 11.28M | 71.17% |
| Dec 31, 2023 | 15.84M | -90.64M | -85.12% |
| Dec 31, 2022 | 106.48M | -417.52M | -79.68% |
| Dec 31, 2021 | 524.00M | 486.49M | 1,296.82% |
| Dec 31, 2020 | 37.51M | 30.23M | 415.23% |
| Dec 31, 2019 | 7.28M | -4.00M | -35.48% |
| Dec 31, 2018 | 11.28M | -1.82M | -13.91% |
| Dec 31, 2017 | 13.11M | -11.99M | -47.78% |
| Dec 31, 2016 | 25.10M | 14.86M | 145.24% |
| Dec 31, 2015 | 10.23M | 4.57M | 80.54% |
| Dec 31, 2014 | 5.67M | 1.62M | 40.07% |
| Dec 31, 2013 | 4.05M | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novavax | 1.06B |
| Ardelyx | 407.32M |
| Monte Rosa Therapeutics | 181.54M |
| AnaptysBio | 169.47M |
| Intellia Therapeutics | 57.53M |
| Capricor Therapeutics | 11.13M |
| Relay Therapeutics | 8.36M |
| AtaiBeckley | 3.02M |
QURE News
- 1 day ago - The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 13, 2026 in uniQure Lawsuit - QURE - PRNewsWire
- 2 days ago - UniQure N.V. (QURE) Securities Fraud: Contact Berger Montague To Discuss Your Rights - Newsfile Corp
- 3 days ago - UNIQURE N.V. (QURE) INVESTOR ALERT Investors With Large Losses in uniQure N.V. - GlobeNewsWire
- 3 days ago - Diamond Hill International Strategy Q4 2025 Portfolio Review - Seeking Alpha
- 14 days ago - Early uniQure Fabry Trial Shows Lasting Enzyme Boost, Safety Watch - Benzinga
- 14 days ago - uniQure Announces Updated Preliminary AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease - GlobeNewsWire
- 22 days ago - Alger Small Cap Focus Fund Q4 2025 Portfolio Update - Seeking Alpha
- 6 weeks ago - uniQure Announces Type A Meeting Scheduled with FDA - GlobeNewsWire